Ad is loading...
EYPT
Price
$9.17
Change
-$1.32 (-12.58%)
Updated
Nov 15 closing price
101 days until earnings call
OCUL
Price
$9.16
Change
-$0.76 (-7.66%)
Updated
Nov 15 closing price
108 days until earnings call
Ad is loading...

EYPT vs OCUL

Header iconEYPT vs OCUL Comparison
Open Charts EYPT vs OCULBanner chart's image
EyePoint Pharmaceuticals
Price$9.17
Change-$1.32 (-12.58%)
Volume$1.02M
CapitalizationN/A
Ocular Therapeutix
Price$9.16
Change-$0.76 (-7.66%)
Volume$1.33M
CapitalizationN/A
EYPT vs OCUL Comparison Chart
Loading...
EYPT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
EYPT vs. OCUL commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EYPT is a Sell and OCUL is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (EYPT: $9.17 vs. OCUL: $9.16)
Brand notoriety: EYPT and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EYPT: 127% vs. OCUL: 107%
Market capitalization -- EYPT: $625.86M vs. OCUL: $1.43B
EYPT [@Biotechnology] is valued at $625.86M. OCUL’s [@Biotechnology] market capitalization is $1.43B. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EYPT’s FA Score shows that 1 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • EYPT’s FA Score: 1 green, 4 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, OCUL is a better buy in the long-term than EYPT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EYPT’s TA Score shows that 5 TA indicator(s) are bullish while OCUL’s TA Score has 5 bullish TA indicator(s).

  • EYPT’s TA Score: 5 bullish, 5 bearish.
  • OCUL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, OCUL is a better buy in the short-term than EYPT.

Price Growth

EYPT (@Biotechnology) experienced а -21.15% price change this week, while OCUL (@Biotechnology) price change was -17.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

EYPT is expected to report earnings on Feb 27, 2025.

OCUL is expected to report earnings on Mar 06, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($1.43B) has a higher market cap than EYPT($626M). OCUL YTD gains are higher at: 105.381 vs. EYPT (-60.320). EYPT has higher annual earnings (EBITDA): -85.85M vs. OCUL (-119.81M). OCUL has more cash in the bank: 460M vs. EYPT (280M). EYPT has less debt than OCUL: EYPT (23.3M) vs OCUL (74.9M). OCUL has higher revenues than EYPT: OCUL (61.1M) vs EYPT (50.4M).
EYPTOCULEYPT / OCUL
Capitalization626M1.43B44%
EBITDA-85.85M-119.81M72%
Gain YTD-60.320105.381-57%
P/E RatioN/AN/A-
Revenue50.4M61.1M82%
Total Cash280M460M61%
Total Debt23.3M74.9M31%
FUNDAMENTALS RATINGS
EYPT vs OCUL: Fundamental Ratings
EYPT
OCUL
OUTLOOK RATING
1..100
6265
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
48
Fair valued
PROFIT vs RISK RATING
1..100
10070
SMR RATING
1..100
9696
PRICE GROWTH RATING
1..100
5736
P/E GROWTH RATING
1..100
27100
SEASONALITY SCORE
1..100
7595

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (48) in the Pharmaceuticals Other industry is in the same range as EYPT (65) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to EYPT’s over the last 12 months.

OCUL's Profit vs Risk Rating (70) in the Pharmaceuticals Other industry is in the same range as EYPT (100) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to EYPT’s over the last 12 months.

OCUL's SMR Rating (96) in the Pharmaceuticals Other industry is in the same range as EYPT (96) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to EYPT’s over the last 12 months.

OCUL's Price Growth Rating (36) in the Pharmaceuticals Other industry is in the same range as EYPT (57) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to EYPT’s over the last 12 months.

EYPT's P/E Growth Rating (27) in the Pharmaceuticals Major industry is significantly better than the same rating for OCUL (100) in the Pharmaceuticals Other industry. This means that EYPT’s stock grew significantly faster than OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EYPTOCUL
RSI
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
86%
Momentum
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
80%
MACD
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 7 days ago
84%
Bullish Trend 12 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
89%
Aroon
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
EYPT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TOLZX16.790.14
+0.84%
DWS RREEF Global Infrastructure R6
RRFDX38.450.02
+0.05%
T. Rowe Price Equity Income R
CDEYX18.31-0.06
-0.33%
Columbia Large Cap Value Inst3
CRFAX12.31-0.07
-0.57%
Calvert Focused Value A
DBOYX25.16-0.23
-0.91%
BNY Mellon Balanced Opportunity Y

EYPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with ATHE. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then ATHE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
-12.58%
ATHE - EYPT
53%
Loosely correlated
-5.56%
OCUL - EYPT
49%
Loosely correlated
-7.66%
LYRA - EYPT
39%
Loosely correlated
-5.56%
CVM - EYPT
36%
Loosely correlated
+0.02%
ORMP - EYPT
35%
Loosely correlated
-4.50%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
-7.66%
EYPT - OCUL
48%
Loosely correlated
-12.58%
RCUS - OCUL
44%
Loosely correlated
-0.44%
PLRX - OCUL
41%
Loosely correlated
-3.27%
RXRX - OCUL
40%
Loosely correlated
-10.64%
ARWR - OCUL
39%
Loosely correlated
-13.26%
More